---
title: "Shanghai MicroPort MedBot Records Cumulative Order Volume for Core Products of Over 100 Units"
description: "Shanghai MicroPort MedBot (Group) recorded a cumulative order volume of over 100 units for the laparoscopic, orthopedic, and vascular interventional core products of the group for 2024, a Friday Hong "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/226142698.md"
published_at: "2025-01-24T10:50:19.000Z"
---

# Shanghai MicroPort MedBot Records Cumulative Order Volume for Core Products of Over 100 Units

> Shanghai MicroPort MedBot (Group) recorded a cumulative order volume of over 100 units for the laparoscopic, orthopedic, and vascular interventional core products of the group for 2024, a Friday Hong Kong bourse filing said. 39 orders were received for Toumai Laparoscopic Surgical Robot, while SkyWalker Orthopedic Surgical Robot saw an order volume of 25 units in 2024. Moreover, R-ONE Vascular Interventional Surgical Robot won purchase order bids from five top public hospitals in Shanghai, the filing said.

Shanghai MicroPort MedBot (Group) recorded a cumulative order volume of over 100 units for the laparoscopic, orthopedic, and vascular interventional core products of the group for 2024, a Friday Hong Kong bourse filing said.

39 orders were received for Toumai Laparoscopic Surgical Robot, while SkyWalker Orthopedic Surgical Robot saw an order volume of 25 units in 2024.

Moreover, R-ONE Vascular Interventional Surgical Robot won purchase order bids from five top public hospitals in Shanghai, the filing said.

### Related Stocks

- [00853.HK - MICROPORT](https://longbridge.com/en/quote/00853.HK.md)
- [ISRG.US - Intuitive Surgical](https://longbridge.com/en/quote/ISRG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 摩根大通增持微创医疗约 89.17 万股 每股作价约 11.09 港元 | 香港联交所最新数据显示，2 月 9 日，摩根大通增持微创医疗 89.1713 万股，每股作价 11.089 港元，总金额约为 988.82 万港元。增持后最新持股数目约为 1.92 亿股，持股比例为 10.02%。 | [Link](https://longbridge.com/en/news/275902053.md) |
| 大涨 320% 后，消息称 “全球大模型第一股” 智谱计划赴沪二次上市 | 智谱计划在完成 5.58 亿美元的香港 IPO 后，赴上海科创板进行二次上市。公司股价在周五上涨 23.4%，创下 496 港元的历史新高，自 1 月 8 日上市以来累计涨幅约 320%。智谱选择 “先港后沪” 的路径，旨在拓宽内地投资者基 | [Link](https://longbridge.com/en/news/275885204.md) |
| 假日健康 “不打烊” 阳光融和守安康 | 阳光融和医院在春节期间提供无假日医疗服务，确保市民在节假日也能享受同质化的医疗服务。医院自 2016 年开诊以来，推行 “无假日医疗”，并在 2021 年推出 “四无一有” 服务模式，确保专家门诊、检查手术、会诊查房及患者服务在假期正常进行 | [Link](https://longbridge.com/en/news/275977171.md) |
| 年报业绩预增换不回股价反弹，春立医疗何时让港股通资金 “解套”？ | 春立医疗于 1 月 29 日发布 2025 年年度业绩预增公告，预计归母净利润为 2.45 亿元至 2.88 亿元，同比增 96.01% 至 130.41%。扣非归母净利润为 2.3 亿元至 2.7 亿元，同比增 142.80% 至 185 | [Link](https://longbridge.com/en/news/276027403.md) |
| 微创机器人-B：联交所就公司 H 股全流通授出上市批准 | 微创机器人-B 宣布已获得联交所批准，将于 2026 年 2 月 13 日上市 598.98 万股 H 股。这些股份来自两名股东，约占公司已发行股份总数的 0.5808%。 | [Link](https://longbridge.com/en/news/275908662.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
